592.57 USD
-2.62
0.44%
At close Jan 17, 4:00 PM EST
After hours
592.57
+0.00
0.00%
1 day
-0.44%
5 days
1.92%
1 month
5.29%
3 months
16.48%
6 months
1.81%
Year to date
4.66%
1 year
21.97%
5 years
279.05%
10 years
175.78%
 

About: McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Employees: 51,000

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

59% more call options, than puts

Call options by funds: $982M | Put options by funds: $619M

5.11% less ownership

Funds ownership: 91.52% [Q2] → 86.41% (-5.11%) [Q3]

6% less funds holding

Funds holding: 1,604 [Q2] → 1,514 (-90) [Q3]

21% less capital invested

Capital invested by funds: $69.3B [Q2] → $54.9B (-$14.3B) [Q3]

22% less repeat investments, than reductions

Existing positions increased: 505 | Existing positions reduced: 649

27% less funds holding in top 10

Funds holding in top 10: 45 [Q2] → 33 (-12) [Q3]

37% less first-time investments, than exits

New positions opened: 108 | Existing positions closed: 172

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$641
8%
upside
Avg. target
$663
12%
upside
High target
$688
16%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
Citigroup
Daniel Grosslight
39% 1-year accuracy
9 / 23 met price target
14%upside
$677
Buy
Maintained
10 Jan 2025
B of A Securities
Michael Cherny
68% 1-year accuracy
25 / 37 met price target
10%upside
$650
Buy
Maintained
6 Jan 2025
Morgan Stanley
Erin Wright
39% 1-year accuracy
9 / 23 met price target
8%upside
$642
Overweight
Maintained
17 Dec 2024
Wells Fargo
Stephen Baxter
24% 1-year accuracy
9 / 38 met price target
8%upside
$641
Equal-Weight
Maintained
13 Dec 2024
Evercore ISI Group
Elizabeth Anderson
33% 1-year accuracy
11 / 33 met price target
15%upside
$680
Outperform
Maintained
7 Nov 2024

Financial journalist opinion

Based on 12 articles about MCK published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Here's Why McKesson (MCK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why McKesson (MCK) is a Strong Value Stock
Positive
Zacks Investment Research
6 days ago
Should Value Investors Buy McKesson (MCK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy McKesson (MCK) Stock?
Positive
Zacks Investment Research
6 days ago
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) concluded the recent trading session at $585.08, signifying a +0.57% move from its prior day's close.
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
Positive
Zacks Investment Research
1 week ago
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Neutral
Business Wire
1 week ago
McKesson Amplify Empowers State Pharmacy Associations Nationwide with Advocacy Funding
IRVING, Texas--(BUSINESS WIRE)--McKesson Amplify is intended to help protect critical pharmacy services and elevate the profession by strengthening the voice of the industry.
McKesson Amplify Empowers State Pharmacy Associations Nationwide with Advocacy Funding
Neutral
Zacks Investment Research
2 weeks ago
McKesson Stock Declines Post Divestiture of Canada-Based Businesses
MCK aims to focus on capital deployment and prioritize investments to strengthen its strategic oncology and biopharma growth platforms.
McKesson Stock Declines Post Divestiture of Canada-Based Businesses
Neutral
Business Wire
2 weeks ago
McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms. Additional details related to the divestiture can be found o.
McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
Positive
Zacks Investment Research
3 weeks ago
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
3 weeks ago
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Neutral
Business Wire
3 weeks ago
McKesson Corporation Announces Third Quarter Fiscal 2025 Earnings Release Date and Participation in January Conference
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025.
McKesson Corporation Announces Third Quarter Fiscal 2025 Earnings Release Date and Participation in January Conference
Charts implemented using Lightweight Charts™